Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia.

Autor:in

Gleixner, Karoline V; Schneeweiss, Mathias; Eisenwort, Gregor; Berger, Daniela; Herrmann, Harald; Blatt, Katharina; Greiner, Georg; Byrgazov, Konstantin; Hoermann, Gregor; Konopleva, Marina; Waliul, Islam; Cumaraswamy, Abbarna A; Gunning, Patrick T; Maeda, Hiroshi; Moriggl, Richard; Deininger, Michael; Lion, Thomas; Andreeff, Michael; Valent, Peter

Schlagwörter

Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Drug Delivery Systems; Drug Resistance, Neoplasmdrug effectsgenetics; Fusion Proteins, bcr-ablantagonists & inhibitorsgeneticsmetabolism; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positivedrug therapygeneticsmetabolism; Male; Middle Aged; Neoplastic Stem Cellsmetabolismpathology; Protein Kinase Inhibitorspharmacology; STAT3 Transcription Factorantagonists & inhibitorsgeneticsmetabolism; STAT5 Transcription Factorantagonists & inhibitorsgeneticsmetabolism

CC Lizenz

CCBYNC

ISSN/eISSN

0390-6078 -

WoS ID

WOS:000408743300020

Titel des Sammelwerks

HAEMATOLOGICA;